- Home
- MHK vs PRAX Comparison
MHK vs PRAX Comparison
Compare MHK & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHK | PRAX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.8B |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MHK | PRAX |
|---|---|---|
| Price | $124.73 | $309.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $135.09 | ★ $503.93 |
| AVG Volume (30 Days) | ★ 740.3K | 599.2K |
| Earning Date | 02-12-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.71 | N/A |
| Revenue | ★ $10,722,900,000.00 | $7,463,000.00 |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | $2.23 | $15,003.90 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $96.24 | $26.70 |
| 52 Week High | $143.13 | $326.91 |
Technical Indicators
Market Signals| Indicator | MHK | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 57.00 |
| Support Level | $116.40 | $304.03 |
| Resistance Level | $121.57 | $323.40 |
| Average True Range (ATR) | 3.57 | 19.01 |
| MACD | -0.09 | -2.11 |
| Stochastic Oscillator | 73.45 | 63.51 |
Price Performance
Historical ComparisonAbout MHK Mohawk Industries Inc.
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.